leisure time
A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.
The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.
advertisement
BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log InNext article： What does generative AI mean for health care? We asked experts
